AVDL Sep 2024 17.500 call
| Previous close | 0.9000 |
| Open | 1.0000 |
| Bid | 0.7500 |
| Ask | 0.9500 |
| Strike | 17.50 |
| Expiry date | 2024-09-20 |
| Day's range | 0.9000 - 1.1500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.32k |
ZacksHarrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GlobeNewswireAvadel Pharmaceuticals to Present at Upcoming Investor Conferences
DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 6 at 10:30 a.m. ET.Goldman Sachs 45th Annual Global Healthcare Conference: Fireside chat on Wednesday, June 12 at 3:20 p.m. ET. A live webcast of these ev
- GlobeNewswire
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 202
